Bausch Health to Reaffirm High-End 2025 Guidance at J.P. Morgan Conference
BHC sits 76% above its 52-week low of $4.25.
Summary
Bausch Health announced it expects to reaffirm its full-year 2025 guidance at the higher end of the range for its core business, excluding Bausch + Lomb, during its presentation at the J.P. Morgan Healthcare Conference.
Key Events · Earnings and Guidance · BHC
-
Guidance Reaffirmation
Bausch Health expects to reaffirm its full-year 2025 guidance at the higher end of the previously provided range, specifically for Bausch Health excluding Bausch + Lomb Corporation.
-
J.P. Morgan Healthcare Conference
The company will provide strategic and business updates during its presentation at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026.
Analysis · BHC · Life Sciences
Bausch Health's announcement to reaffirm its full-year 2025 guidance at the higher end of the range, specifically for Bausch Health excluding Bausch + Lomb Corporation, signals management's confidence in its operational performance. This update, provided ahead of a major industry conference, suggests a positive outlook and could reassure investors regarding the company's financial trajectory for the core business.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 29.2% of the 1496 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.63%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BHC was trading at $7.48 on NYSE in the Life Sciences sector, with a market capitalization of approximately $2.8B. The 52-week trading range was $4.25 to $8.69. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.